taniborbactam   Click here for help

GtoPdb Ligand ID: 10774

Synonyms: VNRX-5133 | VNRX5133
PDB Ligand
Compound class: Synthetic organic
Comment: Taniborbactam (VNRX-5133) is a clinical stage, injectable, broad-spectrum β-lactamase inhibitor [1,3]. It has activity against both serine- and metallo-β-lactamases (e.g. oxacillinase, Klebsiella pneumoniae carbapenemase, New Delhi metallo-beta-lactamase, Verona integron-encoded metallo-beta-lactamase and extended spectrum beta-lactamase) [4]. Taniborbactam will be administered alongside the cephalosporin antibacterial cefepime. It is being developed by Venatorx Pharmaceuticals in partnership with the Global Antibiotic Research & Development Partnership (GARDP).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 5
Rotatable bonds 8
Topological polar surface area 133.91
Molecular weight 389.21
XLogP 1.19
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NCCNC1CCC(CC1)CC(=O)N[C@H]1Cc2cccc(c2OB1O)C(=O)O
Isomeric SMILES NCCNC1CCC(CC1)CC(=O)N[C@H]1Cc2cccc(c2OB1O)C(=O)O
InChI InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
InChI Key PFZUWUXKQPRWAL-PXCJXSSVSA-N
No information available.
Summary of Clinical Use Click here for help
Taniborbactam is being investigated in combination with cefepime for the treatment of complicated urinary tract infections (cUTIs).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04951505 Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects Phase 1 Interventional Venatorx Pharmaceuticals, Inc.
NCT03690362 VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment Phase 1 Interventional Venatorx Pharmaceuticals, Inc. 2
NCT03840148 Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Phase 3 Interventional VenatoRx Pharmaceuticals, Inc. The combination of cefepime + taniborbactam has a similar safety profile to that of meropenem and is superior for the treatment of cUTIs. 5